De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances.

[1]  R. Lynch,et al.  Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy , 2020, British journal of haematology.

[2]  Ying Li,et al.  Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use , 2019, Biology Direct.

[3]  H. Kim,et al.  Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors , 2019, PloS one.

[4]  N. Ghosh,et al.  Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell DLBCL. , 2019, Blood.

[5]  Mingzhi Zhang,et al.  Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens , 2019, Blood and lymphatic cancer : targets and therapy.

[6]  G. Salles,et al.  Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. , 2019, Blood.

[7]  Yuka Suzuki,et al.  Immune evasion‐related extranodal large B‐cell lymphoma: A report of six patients with neoplastic PD‐L1‐positive extranodal diffuse large B‐cell lymphoma , 2019, Pathology international.

[8]  Hui Zhou,et al.  Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma , 2019, Hematology.

[9]  H. Yamauchi,et al.  Bearing 19q13 aberration predicts poor prognosis in non‐germinal centre type of CD5+DLBCL , 2018, British journal of haematology.

[10]  Michael L. Wang,et al.  B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. , 2018, Blood.

[11]  A. López-Guillermo,et al.  Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma , 2018, Haematologica.

[12]  Junmin Li,et al.  Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma , 2018, Leukemia & lymphoma.

[13]  K. Ohshima,et al.  Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell Iymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study. , 2018 .

[14]  Yifei Liu,et al.  Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review , 2018, Cancer biology & therapy.

[15]  Z. Estrov,et al.  The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide , 2018, Front. Immunol..

[16]  N. Nishimura,et al.  BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. , 2017, Blood.

[17]  T. Gooley,et al.  Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. , 2017, Cancer research.

[18]  Hsu-Ping Kuo,et al.  Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma , 2017, Molecular Cancer Therapeutics.

[19]  Y. Oki,et al.  Prognostic impact of CD5 expression in diffuse large B‐cell lymphoma in patients treated with rituximab‐EPOCH , 2017, European journal of haematology.

[20]  T. Kipps,et al.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Isenberg,et al.  CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes , 2016, Cellular & Molecular Immunology.

[22]  Yi-qun Huang,et al.  [Rituximab plus Autologous Hemotopoietic Stem Cell Transplantation for The Treatment of CD5 Positive Diffuse Large B Cell Lymphoma with Autoimmune Hemolytic Anemia]. , 2016, Zhongguo shi yan xue ye xue za zhi.

[23]  G. Lozanski,et al.  De novo CD5+ diffuse large B‐cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort , 2016, American journal of hematology.

[24]  Wei Zhang,et al.  CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks , 2016, Oncogene.

[25]  K. Miyazaki.  [CD5-positive DLBCL: molecular basis and treatment strategies]. , 2015, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[26]  Kyoko Kobayashi,et al.  Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression , 2015, International Journal of Hematology.

[27]  W. Choi,et al.  Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries , 2015, Oncotarget.

[28]  W. Dalton,et al.  The tumor microenvironment shapes hallmarks of mature B-cell malignancies , 2015, Oncogene.

[29]  A. Grañena,et al.  CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival , 2015, The Journal of pathology.

[30]  W. Choi,et al.  Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma , 2015, Oncotarget.

[31]  R. Gascoyne,et al.  Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Rosenwald,et al.  Diffuse Large B-cell Lymphomas of Immunoblastic Type Are a Major Reservoir for MYC-IGH Translocations , 2015, The American journal of surgical pathology.

[33]  A. Kamal,et al.  Novel Role for NFAT3 in ERK-Mediated Regulation of CXCR4 , 2014, PloS one.

[34]  J. Friedberg,et al.  Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. , 2014, The Lancet. Oncology.

[35]  H. Matsuoka,et al.  Tandem triplication of the BCL2 gene in CD5-positive intravascular large B cell lymphoma with bone marrow involvement , 2014, Annals of Hematology.

[36]  K. Takata,et al.  De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression , 2013, Diagnostic Pathology.

[37]  M. Shipp,et al.  PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies , 2013, Clinical Cancer Research.

[38]  J. Pers,et al.  CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte. , 2012, Autoimmunity reviews.

[39]  T. Witzig,et al.  Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. , 2012, Blood.

[40]  M. Taniwaki,et al.  Cytogenetic analysis of de novo CD5‐positive diffuse large B‐cell lymphoma , 2011, Asia-Pacific journal of clinical oncology.

[41]  T. Molina,et al.  Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.

[42]  D. Ennishi,et al.  CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  A. Rosenwald,et al.  Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. , 2011, Blood.

[44]  J. Pers,et al.  CD5 Promotes IL-10 Production in Chronic Lymphocytic Leukemia B Cells through STAT3 and NFAT2 Activation , 2011, The Journal of Immunology.

[45]  H. Nakamine,et al.  Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  R. Suzuki,et al.  The therapeutic effect of rituximab on CD5‐positive and CD5‐negative diffuse large B‐cell lymphoma , 2009, Hematological oncology.

[47]  D. Ennishi,et al.  CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  M. Taniwaki,et al.  De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients , 2008, Haematologica.

[49]  Jozo Delic,et al.  Natural Phosphorylation of CD5 in Chronic Lymphocytic Leukemia B Cells and Analysis of CD5-Regulated Genes in a B Cell Line Suggest a Role for CD5 in Malignant Phenotype1 , 2007, The Journal of Immunology.

[50]  P. Murray.  The JAK-STAT Signaling Pathway: Input and Output Integration1 , 2007, The Journal of Immunology.

[51]  C. Burgaleta,et al.  Dose‐adjusted EPOCH plus rituximab is an effective regimen in patients with poor‐prognostic untreated diffuse large B‐cell lymphoma: results from a prospective observational study , 2007, British journal of haematology.

[52]  Shigeo Nakamura,et al.  Expression profiling analysis of the CD5+ diffuse large B‐cell lymphoma subgroup: Development of a CD5 signature , 2006, Cancer science.

[53]  T. Kipps,et al.  CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.

[54]  L. Staudt,et al.  BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  H. Tagawa,et al.  Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. , 2005, Blood.

[56]  P. Lydyard,et al.  B Cell Response to Surface IgM Cross-Linking Identifies Different Prognostic Groups of B-Chronic Lymphocytic Leukemia Patients 1 , 2005, The Journal of Immunology.

[57]  T. Yoshino,et al.  Cytogenetic features of de novo CD5‐positive diffuse large B‐cell lymphoma: Chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival , 2005, Genes, chromosomes & cancer.

[58]  G. Schettini,et al.  CXCR4 Activation Induces Epidermal Growth Factor Receptor Transactivation in an Ovarian Cancer Cell Line , 2004, Annals of the New York Academy of Sciences.

[59]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[60]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[61]  H. Tagawa,et al.  Analysis of chromosomal imbalances in de novo CD5‐positive diffuse large‐B‐cell lymphoma detected by comparative genomic hybridization , 2004, Genes, chromosomes & cancer.

[62]  T. Molina,et al.  Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.

[63]  E. Lam,et al.  Cyclin D2 controls B cell progenitor numbers , 2003, Journal of leukocyte biology.

[64]  J. Armitage,et al.  International Collaborative Group against Primary CNS Lymphomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  H. Müller-Hermelink,et al.  Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. , 2003, Blood.

[66]  G. Bismuth,et al.  Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. , 2002, Blood.

[67]  S. Wong,et al.  Peritoneal CD5+ B-1 Cells Have Signaling Properties Similar to Tolerant B Cells* , 2002, The Journal of Biological Chemistry.

[68]  T. Chiles,et al.  Requirement for a hsp90 Chaperone-dependent MEK1/2-ERK Pathway for B Cell Antigen Receptor-induced Cyclin D2 Expression in Mature B Lymphocytes* , 2002, The Journal of Biological Chemistry.

[69]  Takashi Akasaka,et al.  De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. , 2002, Blood.

[70]  Georges Bismuth,et al.  CD5-Negative Regulation of B Cell Receptor Signaling Pathways Originates from Tyrosine Residue Y429 Outside an Immunoreceptor Tyrosine-Based Inhibitory Motif1 , 2002, The Journal of Immunology.

[71]  J. Glassford,et al.  Vav Is Required for Cyclin D2 Induction and Proliferation of Mouse B Lymphocytes Activated via the Antigen Receptor* , 2001, The Journal of Biological Chemistry.

[72]  T. Kurosaki,et al.  Regulation of the phospholipase C‐γ2 pathway in B cells , 2000, Immunological reviews.

[73]  Y. Arimura,et al.  Src Homology Region 2 (SH2) Domain-Containing Phosphatase-1 Dephosphorylates B Cell Linker Protein/SH2 Domain Leukocyte Protein of 65 kDa and Selectively Regulates c-Jun NH2-Terminal Kinase Activation in B Cells1 , 2000, The Journal of Immunology.

[74]  P. Bruhns,et al.  The Pseudo-immunoreceptor Tyrosine-based Activation Motif of CD5 Mediates Its Inhibitory Action on B-cell Receptor Signaling* , 2000, The Journal of Biological Chemistry.

[75]  V. Mordvinov,et al.  Role of nuclear factor of activated T cells (NFAT) in the expression of interleukin-5 and other cytokines involved in the regulation of hemopoetic cells. , 1999, The international journal of biochemistry & cell biology.

[76]  M. Seto,et al.  Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes , 1999, Leukemia.

[77]  H. Shiku,et al.  De novo CD5‐positive diffuse large B‐cell lymphoma: clinical characteristics and therapeutic outcome , 1999, British journal of haematology.

[78]  J. Kinet,et al.  Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1 , 1999, Oncogene.

[79]  S. Kanner,et al.  CD5 Negatively Regulates the T-Cell Antigen Receptor Signal Transduction Pathway: Involvement of SH2-Containing Phosphotyrosine Phosphatase SHP-1 , 1999, Molecular and Cellular Biology.

[80]  H. Shiku,et al.  De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. , 1998, Blood.

[81]  A. Fauci,et al.  Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. , 1997, Journal of immunology.

[82]  G. Pizzolo,et al.  In leukaemic CD5+ B cells the expression of BCL‐2 gene family is shifted toward protection from apoptosis , 1996, British journal of haematology.

[83]  T. Rothstein.  Signals and susceptibility to programmed death in b cells. , 1996, Current opinion in immunology.

[84]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[85]  T. Yoshino,et al.  Expression of Bcl-2 protein and Bcl-2 mRNA in normal and neoplastic lymphoid tissues. , 1994, Leukemia & lymphoma.

[86]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[87]  K. Young,et al.  Diffuse large B-cell lymphoma. , 2018, Pathology.

[88]  K. Miyazaki.  Treatment of Diffuse Large B-Cell Lymphoma. , 2016, Journal of clinical and experimental hematopathology : JCEH.

[89]  Zhang Jianbo,et al.  Mechanism of action of EBV, Bcl-2, p53, c-Myc and Rb in non-Hodgkin's lymphoma. , 2016 .

[90]  W. Song,et al.  Mechanism of action of EBV, Bcl-2, p53, c-Myc and Rb in non-Hodgkin's lymphoma. , 2016, European review for medical and pharmacological sciences.

[91]  T. Nagasawa.  The chemokine CXCL12 and regulation of HSC and B lymphocyte development in the bone marrow niche. , 2007, Advances in experimental medicine and biology.

[92]  T. Molina,et al.  Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  Ilya Shmulevich,et al.  Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. , 2003, Cancer research.

[94]  T. Kipps.  The CD5 B cell. , 1989, Advances in immunology.